Analyst / Investor Meet - Intimation
We wish to inform you that senior management team of Suven Life Sciences is giving corporate presentation in 'B&K;'s Investor Conference Emergent India- 2017' with fund managers and analysts meet organized in Mumbai by B&K; Securities on 12th December, 2017. Please find enclosed Corporate Presentation. Press Release / Media Release
Suven Life Sciences secures Product Patents in India and USA
Suven Life Sciences, previously in Trendlyne's focus, rises on patent win
Hyderabad-based Suven LifeSciences is a pharma firm written about by Trendlyne first in Feb 2017, when the firm won multiple patents for the treatment of Alzheimer's and other neurodegenerative diseases. The company has now received product patent recognition from Norway and Eurasia for products in the same neuro-degenerative space. The firm's share price has been rising on the news, despite the tepid market. The company has been cash positive despite significant spending on R&D; - annually, Suven spends around 14% of its sales on proprietary NCE research, which has been till date, not a revenue generator. A note of caution however remains in that Alzheimer's is a notoriously difficult disease to treat, and therapy tends to fail in large-scale usage after successful trials. One of the drugs in development by Suven, RVT-101, has released phase-2 data that was disappointing. Suven is one of the smaller firms in the pharma space with a distinct R&D; focus that has paid off so far in rising YoY revenues an EBITDA margins, which as per the most recent quarter are over 46%. Suven gets product patent from Eurasia, Norway
Suven Life Sciences has secured a product patent each from Eurasia and Norway for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2034 and... Press Release / Media Release
Suven Life Sciences secures Product Patents in Eurasia and Norway Suven Life Sciences gets patent from Hong Kong, US, India; stock gains 3%
The patents are valid till 2032, 2030 and 2034, respectively, the company said in a BSE filing Press Release / Media Release
Suven Life Sciences secures Product Patents in Hong Kong, India and USA Press Release / Media Release
'Suven Life sciences presenting at Neuroscience 2017 at Washington DC'. Suven Life Sciences Q2 net climbs 20% to Rs 32 cr
Suven Life Sciences reported a 19.5 per cent increase in net profit to Rs 31.74 crore for the second quarter ended September 30. The company had posted a net profit of Rs 26.55 crore in the same... 